Table 2.

Effect of nasal steroid treatment on symptom scores in different BMI groups

BMI group	Placebo	Nasal Mometasone	P value
	Change from V2 to V5*	Change from V2 to V5*
FEV1 (% predicted)
< 25	0.82 (−1.22, 2.86)	1.69 (−1.04, 4.41)	0.61
25–29.9	1.68 (−2.71, 6.08)	−3.18 (−7.57, 1.22)	0.12
> 30	−0.06 (−3.43, 3.30)	−1.99 (−5.11, 1.12)	0.41
FVC (% predicted)
< 25	−0.14 (−1.66, 1.39)	2.64 (−0.61, 4.68)	0.03
25–29.9	1.90 (−1.92, 5.72)	−2.61 (−6.43, 1.21)	0.10
> 30	−0.79 (−3.81, 2.24)	−2.10 (−4.90, 0.69)	0.53
ASUI (↑)
< 25	0.09 (0.03, 0.14)	0.14 (0.07, 0.21)	0.21
25–29.9	0.04 (−0.02, 0.11)	0.10 (0.03, 0.16)	0.25
> 30	−0.008 (−0.06, 0.04)	0.07 (0.03, 0.12)	0.02
ACT (↑)
< 25	3.34 (2.07, 4.61)	2.93 (1.37, 4.49)	0.68
25–29.9	2.38 (0.83, 3.92)	3.96 (2.41, 5.51)	0.15
> 30	1.98 (0.76, 3.19)	2.14 (1.00, 3.27)	0.85
SNOT22 (↓)
< 25	−4.93 (−10.12, 0.27)	−13.10 (−19.57, −6.63)	0.053
25–29.9	−8.12 (−15.19, −1.05)	−13.90 (−21.18, −6.62)	0.26
> 30	−6.25 (−12.37, −0.14)	−10.08 (−15.69, −4.47)	0.36

Numbers shown are mean and SD

↑ higher score indicative of better control, ↓ lower score indicative of better control

V2 is baseline visit, V5 is end of study visit.